US Stock MarketDetailed Quotes

DARE Dare Bioscience

Watchlist
  • 3.2600
  • -0.1000-2.98%
Close Sep 20 16:00 ET
  • 3.2590
  • -0.0010-0.03%
Post 20:01 ET
27.86MMarket Cap-2810P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Aug 26 07:20
    Update
    $Dare Bioscience (DARE.US)$ Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
    Benzinga· 5 mins ago
    Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.
    Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in wo...
    1
    Jaguar8
    Jaguar8
    Aug 26 07:00
    NEWS
    $Dare Bioscience (DARE.US)$
    Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
    Daré Bioscience (NASDAQ: DARE) announced the publication of safety data from its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine.
    The study, involving 1,357 sexual experiences, showed that the topical cream was safe and well-tolerated by women with female s...
    Trytosaveabit
    Trytosaveabit
    Aug 13 07:27
    Update
    $Dare Bioscience (DARE.US)$ Daré Bioscience Announces Publication In The Journal Of Sexual Medicine Of Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
    Benzinga· 4 mins ago
    Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies
    Longer recall intervals for PRO assessments are less burdensome to cl...
    Jaguar8
    Jaguar8
    Aug 12 15:03
    NEWS
    $Dare Bioscience (DARE.US)$
    Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
    Daré Bioscience (NASDAQ: DARE) reported Q2 2024 financial results and provided a company update. Key highlights include:
    1. Ongoing enrollment in the OvaprenePhase 3 contraceptive efficacy study across the U.S.
    2. Progress on Sildenafil Cream, 3.6% for female sexual arousal disorder, awaiting FDA feedback on Phase 3 study design.
    3. Cash and cash equivalents of $16.4 million a...
    Jaguar8
    Jaguar8
    Jul 19 08:18
    NEWS
    $Dare Bioscience (DARE.US)$
    Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data